2018, Vol. 1, Issue 2, Part A
A study of hemodynamics when different doses of dexmedetomidine is used with propofol as an inducing agent
Author(s): Dr. Shashikiran DS and Dr. Chetan B Bhat
Abstract: Dexmedetomidine is a potent and highly selective α2 adrenoreceptor agonist which was approved for clinical use in 1999 and recently introduced in India. It has all the above mentioned properties and can impart significant benefits in the peri-operative use. In spite of the multiple desirable effects of dexmedetomidine, bradycardia and hypotension remain clinically significant adverse effects. High doses of dexmedetomidine can result in a decreased heart rate and cardiac output, with a biphasic dose response relation for BP. High doses of dexmedetomidine can also be a cause of systemic and pulmonary hypertension.
DOI: 10.33545/26643766.2018.v1.i2a.206
Pages: 25-27 | Views: 746 | Downloads: 369
Download Full Article: Click Here
How to cite this article:
Dr. Shashikiran DS, Dr. Chetan B Bhat. A study of hemodynamics when different doses of dexmedetomidine is used with propofol as an inducing agent. Int J Med Anesthesiology 2018;1(2):25-27. DOI: 10.33545/26643766.2018.v1.i2a.206
